Pyxis Oncology (PYXS) Profit After Tax (2020 - 2025)
Pyxis Oncology (PYXS) reported Profit After Tax of -$18.1 million for Q4 2025, up 49.06% year-over-year from -$12.1 million in Q4 2024, and up 17.74% quarter-over-quarter from -$22.0 million in Q3 2025.
Pyxis Oncology (PYXS) Profit After Tax (2020 - 2025) Analysis & Trends
Pyxis Oncology (PYXS) has 6 years of Profit After Tax data on file, last reported at -$18.1 million in Q4 2025.
- Profit After Tax for Q4 2025 came in at -$18.1 million, up 49.06% year-over-year; the trailing twelve-month figure through Dec 2025 was -$79.6 million (down 3.01% YoY), and the FY2025 annual result was -$79.6 million, down 2.93% from the prior year.
- Profit After Tax advanced to -$18.1 million in Q4 2025 per PYXS's latest filing, from -$22.0 million in the prior quarter.
- Over five years, Profit After Tax peaked at -$3.3 million in Q1 2024 and troughed at -$36.8 million in Q1 2021.
- A 5-year average of -$21.4 million and a median of -$20.2 million in 2023 frame the typical range for Profit After Tax.
- The sharpest annual moves came in 2024 and 2025: Profit After Tax soared 83.08% in 2024, then slumped 549.82% in 2025.
- A 5-year view of Profit After Tax shows it stood at -$16.9 million in 2021, then tumbled by 113.71% to -$36.1 million in 2022, then surged by 56.81% to -$15.6 million in 2023, then slumped by 127.76% to -$35.5 million in 2024, then jumped by 49.06% to -$18.1 million in 2025.
- Business Quant data shows PYXS's Profit After Tax at -$18.1 million in Q4 2025, -$22.0 million in Q3 2025, and -$18.4 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.90 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -753,254.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.74 Mn |
| 10 | Pyxis Oncology | 125.84 Mn | 108.95 Mn | 8.65 Mn | -18.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -18.10 Mn |
| Sep 30, 2025 | -22.00 Mn |
| Jun 30, 2025 | -18.35 Mn |
| Mar 31, 2025 | -21.16 Mn |
| Dec 31, 2024 | -35.53 Mn |
| Sep 30, 2024 | -21.20 Mn |
| Jun 30, 2024 | -17.30 Mn |
| Mar 31, 2024 | -3.26 Mn |
| Dec 31, 2023 | -15.60 Mn |
| Sep 30, 2023 | -23.05 Mn |
| Jun 30, 2023 | -15.90 Mn |
| Mar 31, 2023 | -19.24 Mn |
| Dec 31, 2022 | -36.12 Mn |
| Sep 30, 2022 | -27.67 Mn |
| Jun 30, 2022 | -25.56 Mn |
| Mar 31, 2022 | -31.38 Mn |
| Dec 31, 2021 | -16.90 Mn |
| Sep 30, 2021 | -14.18 Mn |
| Jun 30, 2021 | -8.15 Mn |
| Mar 31, 2021 | -36.83 Mn |